IS

IS is a pharmaceutical company focused on developing treatments for rare diseases, including Duchenne muscular dystrophy and gene therapies.

Why it’s in the news: It is in the news due to its drug for Duchenne muscular dystrophy being discussed in the context of clinical trial decision-making.

Latest on IS

• Ex-Zambian minister killed in security raid on opposition
• German neo-Nazi suspected of deadly 1970 fire at Jewish retirement home
• This fascinating folding e-bike is lighter than Brompton’s lightest electric bike
• Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
• STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
• Comcast is turning tens of millions of routers into motion detectors

Connections

3 entities linked to IS across the news graph.